Repligen Swings to Profit, Revenue Jumps on Strong Product Sales

TL;DR

**RGEN is back in the black with surging revenue and net income, making it a strong buy for growth-oriented investors.**

AI Summary

REPLIGEN CORP (RGEN) reported a significant turnaround in its financial performance for the three and nine months ended September 30, 2025. Total revenue for the three months increased to $188.805 million from $154.871 million in the prior year, a 21.9% increase. Net income for the three months surged to $14.911 million, a substantial improvement from a net loss of $654 thousand in the same period of 2024. For the nine months, total revenue grew to $540.343 million from $466.892 million, an increase of 15.7%, and net income rose to $35.607 million from $8.355 million, a 326% increase. Key business changes include a significant increase in goodwill to $1.112 billion from $1.030 billion at December 31, 2024, indicating recent acquisitions. The company also saw a positive foreign currency translation adjustment of $48.426 million for the nine months ended September 30, 2025, compared to $3.185 million in the prior year. Risks include ongoing business and economic uncertainty from global geopolitical conflicts, supply chain challenges, foreign currency fluctuations, and cost pressures on customers' purchasing patterns, which make financial estimates more difficult to calculate. Strategic outlook involves evaluating new accounting guidance, such as ASU 2024-03 on expense disaggregation, which could impact future disclosures.

Why It Matters

This strong performance signals a robust recovery and growth trajectory for Repligen, which is crucial for investors seeking stability and upside in the volatile biotech tools sector. The significant increase in net income and revenue, coupled with strategic acquisitions reflected in higher goodwill, suggests effective management and market penetration. For employees, this indicates a healthy company with potential for continued investment in R&D and expansion. Customers benefit from a financially stable supplier of critical bioprocessing components. In the broader market, Repligen's growth could intensify competition, particularly against peers like Danaher and Sartorius, as it expands its market share and product offerings.

Risk Assessment

Risk Level: medium — The company explicitly states that "business and economic uncertainty resulting from global geopolitical conflicts, supply chain challenges, foreign currency fluctuations and cost pressures on customers' purchasing patterns has made such estimates more difficult to calculate." While net income is up significantly to $35.607 million for the nine months, cash provided by operating activities decreased to $91.713 million from $136.218 million in the prior year, indicating potential operational cash flow challenges despite higher profitability.

Analyst Insight

Investors should consider RGEN a strong growth play given the substantial increase in net income and revenue. Monitor the impact of global economic uncertainties on future guidance and cash flow from operations, as a decline in operating cash flow to $91.713 million from $136.218 million could signal underlying pressures.

Financial Highlights

revenue

$540.3M

net Income

$35.6M

cash Position

$748.7M

revenue Growth

+15.7%

Revenue Breakdown

Key Numbers

• $188.8M — Q3 2025 Total Revenue (Up 21.9% from $154.9M in Q3 2024, indicating strong product sales growth.)
• $14.9M — Q3 2025 Net Income (A significant turnaround from a $0.7M net loss in Q3 2024, demonstrating improved profitability.)
• $540.3M — YTD 2025 Total Revenue (Increased 15.7% from $466.9M in YTD 2024, reflecting sustained growth.)
• $35.6M — YTD 2025 Net Income (A 326% increase from $8.4M in YTD 2024, highlighting substantial profit expansion.)
• $1.11B — Goodwill (Increased from $1.03B at December 31, 2024, suggesting recent strategic acquisitions.)
• $91.7M — YTD 2025 Cash from Operations (Decreased from $136.2M in YTD 2024, indicating a potential shift in operational cash efficiency despite higher net income.)
• $89.7M — YTD 2025 Cash Used in Investing (Increased significantly from $21.6M in YTD 2024, primarily due to acquisitions net of cash acquired.)
• $748.7M — Cash and Cash Equivalents (Slightly decreased from $757.4M at the beginning of the period, reflecting investment activities.)

Key Players & Entities

• REPLIGEN CORP (company) — Registrant
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board
• $188.805 million (dollar_amount) — Total revenue for three months ended September 30, 2025
• $154.871 million (dollar_amount) — Total revenue for three months ended September 30, 2024
• $14.911 million (dollar_amount) — Net income for three months ended September 30, 2025
• $654 thousand (dollar_amount) — Net loss for three months ended September 30, 2024
• $540.343 million (dollar_amount) — Total revenue for nine months ended September 30, 2025
• $35.607 million (dollar_amount) — Net income for nine months ended September 30, 2025
• $1.112 billion (dollar_amount) — Goodwill as of September 30, 2025
• $91.713 million (dollar_amount) — Total cash provided by operating activities for nine months ended September 30, 2025

FAQ

Risk Factors

• Global Geopolitical Conflicts [high — market]: Ongoing business and economic uncertainty stemming from global geopolitical conflicts poses a risk. This uncertainty makes financial estimates more difficult to calculate.
• Supply Chain Challenges [medium — operational]: The company faces ongoing supply chain challenges, which can impact production and delivery. These challenges contribute to the difficulty in making precise financial estimates.
• Foreign Currency Fluctuations [medium — financial]: Significant foreign currency translation adjustments, such as the $48.426 million gain for the nine months ended September 30, 2025, highlight the impact of currency volatility. This volatility adds complexity to financial forecasting.
• Customer Cost Pressures [medium — market]: Cost pressures on customers' purchasing patterns can affect demand for Repligen's products. This economic sensitivity makes future revenue streams less predictable.

Industry Context

Repligen operates in the life sciences industry, focusing on bioprocessing technologies. The sector is characterized by innovation, significant R&D investment, and a complex regulatory environment. Key trends include the growing demand for biologics, the need for efficient and scalable manufacturing solutions, and increasing consolidation through mergers and acquisitions.

Regulatory Implications

The company must navigate evolving accounting standards, such as ASU 2024-03 on expense disaggregation, which will require careful implementation and may affect future financial disclosures. Compliance with industry-specific regulations for life sciences products remains a critical operational aspect.

What Investors Should Do

1. Monitor acquisition impact
2. Analyze cash flow trends
3. Assess foreign currency exposure

Glossary

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. It represents the future economic benefits arising from assets acquired in a business combination that are not individually identified and recognized. (The increase in goodwill to $1.112 billion from $1.030 billion indicates that Repligen has made significant acquisitions, which is a key driver of its growth strategy and impacts its balance sheet.)

Foreign Currency Translation Adjustment

An adjustment made to account for the changes in the value of a company's foreign currency-denominated assets and liabilities when translated into the company's reporting currency. These adjustments can impact comprehensive income. (The substantial positive adjustment of $48.426 million for the nine months ended September 30, 2025, compared to $3.185 million in the prior year, shows a significant favorable impact from currency movements on the company's financial statements.)

ASU 2024-03

Accounting Standards Update 2024-03, which provides guidance on expense disaggregation. This update aims to improve the transparency and comparability of financial reporting by requiring companies to provide more detailed breakdowns of their expenses. (Repligen is evaluating this new accounting guidance, which could lead to changes in how they present their financial information in future filings, potentially impacting the comparability of historical data.)

Year-Over-Year Comparison

Repligen Corp. has demonstrated a strong financial turnaround compared to the prior year. Total revenue for the three months ended September 30, 2025, increased by 21.9% to $188.8 million, and net income shifted from a loss of $0.7 million to a profit of $14.9 million. For the nine-month period, revenue grew 15.7% to $540.3 million, with net income surging 326% to $35.6 million. The company's balance sheet reflects increased strategic activity, with goodwill rising due to acquisitions. However, cash from operations has decreased, and cash used in investing has significantly increased, indicating a shift in capital deployment.

Key Financial Figures

• $0.01 — h registered Common Stock , par value $0.01 per share RGEN The Nasdaq Global Se

Filing Documents

• rgen-20250930.htm (10-Q) — 3004KB
• rgen-ex31_1.htm (EX-31.1) — 15KB
• rgen-ex31_2.htm (EX-31.2) — 15KB
• rgen-ex32_1.htm (EX-32.1) — 20KB
• 0001193125-25-264666.txt ( ) — 13673KB
• rgen-20250930.xsd (EX-101.SCH) — 1802KB
• rgen-20250930_htm.xml (XML) — 2968KB

Financial Statements

Financial Statements 3 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (Unaudited) 3 Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 32 PART II. OTHER INFORMATION 34 Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Defaults Upon Senior Securities 34 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 34 Item 6. Exhibits 35

Signatures

Signatures 36 2 Table of Contents

FINANCIAL INF ORMATION

PART I. FINANCIAL INF ORMATION

Financia l Statements

ITEM 1. Financia l Statements REPLIGEN CORPORATION CONDENSED CONSOLIDATED BAL ANCE SHEETS (Unaudited, amounts in thousands, except share data) September 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 748,747 $ 757,355 Accounts receivable, net of reserves of $ 2,274 and $ 1,832 at September 30, 2025 and December 31, 2024, respectively 148,970 134,115 Inventories, net 160,320 142,964 Prepaid expenses and other current assets 38,448 31,607 Total current assets 1,096,485 1,066,041 Noncurrent assets: Property, plant and equipment, net 188,927 197,738 Intangible assets, net 395,442 397,897 Goodwill 1,112,735 1,030,995 Deferred tax assets 856 749 Operating lease right of use assets 124,161 135,378 Other noncurrent assets 5,105 868 Total noncurrent assets 1,827,226 1,763,625 Total assets $ 2,923,711 $ 2,829,666 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 29,426 $ 32,134 Operating lease liabilities 19,314 15,104 Contingent consideration 5,107 17,126 Accrued liabilities 77,289 62,423 Total current liabilities 131,136 126,787 Noncurrent liabilities: Convertible Senior Notes due 2028, net 537,927 525,567 Deferred tax liabilities 20,135 22,775 Noncurrent operating lease liabilities 131,626 145,576 Noncurrent contingent consideration 2,478 19,662 Other noncurrent liabilities 17,322 16,581 Total noncurrent liabilities 709,488 730,161 Total liabilities 840,624 856,948 Commitments and contingencies (Note 11) Stockholders' equity: Preferred stock, $ 0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding — — Common stock, $ 0.01 par value; 80,000,000 shares authorized; 56,283,321 shares at September 30, 2025 and 56,091,677 shares at December 31, 2024 issued and outstanding 563 561 Additional paid-i

View Full Filing

View this 10-Q filing on SEC EDGAR